Visual Neurophisiology
2024 Activity indicators
- 4 competitive national public projects: ISCIII, MINECO/MICIIN
- 1 competitive contracts HR
- 9 publications
- IF: 30.40
- Q1 publications: 6 (67%)
- National public agency project evaluators: 1 PI
- Members of editorial committees: 1 PI
- 2 actions with an impact on society: a conference and a participation in round table
Milestones
- The group has demonstrated that measurement of Multifocal Visual Evoked Potential (mfVEP) can serve as an independent risk factor to predict conversion to Multiple Sclerosis (MS) in individuals with Radiologically Isolated Syndrome.
- Progress in the validation of "photoswitches" in animal models of blindness. These substances respond to light and allow light responses to be generated even in the total absence of retinal photoreceptors.
- Funding obtained for the development of new therapeutic interventions for Parkinson's disease, in the framework of a project coordinated with researchers from CSIC. In this project, artificial intelligence will be used to the design of new compounds that modulate synaptic activity.
- Dr. María José Casarejos, specialist in animal models of neurodegeneration and liquid chromatography for the measurement of neurotransmitters, joined the team. Her integration has made it possible to undertake new lines of research, such as the study of the dopaminergic circuit of the retina.
- Strengthening and expansion of the collaborations of the group with several research groups belonging to the Universidad Autónoma de Madrid, the Universidad Francisco de Vitoria and the CSIC. This expansion has been possible thanks to the identification of important synergies between the study of neurodegenerative and inflammatory diseases and to the extensive experience of the group in the visual system, with a particular focus on the retina.
Bibliometrics
ARTICLES | ACCUM. IF | MEAN IF | ARTICLES Q1 OR Q2 | % IN Q1 OR Q2 | ARTICLES D1 | % IN D1 | |
---|---|---|---|---|---|---|---|
2020 | 11 | 60.90 | 6.09 | 9 | 82 | 3 | 27 |
2021 | 8 | 50.32 | 6.29 | 8 | 100 | 1 | 15 |
2022 | 7 | 61.88 | 8.84 | 7 | 100 | 1 | 14 |
2023 | 6 | 41.61 | 6.94 | 6 | 100 | 3 | 50 |
2024 | 9 | 30.40 | 3.38 | 7 | 78 | 0 | 0 |
41 | 245.11 | 6.31 | 37 | 92 | 8 | 20 | |
* Only original articles, editorial material, guidelines and reviews.